Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
Fizazi K, Azad AA, Matsubara N, Carles J, Fay AP, De Giorgi U, Joung JY, Fong PCC, Voog E, Jones RJ, Shore ND, Dunshee C, Zschäbitz S, Oldenburg J, Ye D, Lin X, Healy CG, Di Santo N, Laird AD, Zohren F, Agarwal N.
Fizazi K, et al. Among authors: di santo n.
Nat Med. 2024 Jan 31. doi: 10.1038/s41591-024-02835-9. Online ahead of print.
Nat Med. 2024.
PMID: 38297094
No abstract available.